Researchers at University College London Hospitals (UCLH) are hailing a groundbreaking trial that has seen several patients with lupus enter remission through an innovative immune system reset treatment. This pioneering approach holds out significant hope for the estimated 50,000 people in the UK living with the autoimmune disease, where 90% of those affected are women typically diagnosed in young adulthood.
One such patient, Katie Tinkler, who was diagnosed with lupus 30 years ago and was once severely debilitated by its effects, has seen a remarkable improvement in her health. Now off all lupus medication, she can enjoy activities like skiing that were previously impossible for her due to the condition's aggressive flare-ups which had damaged her heart, lungs, and kidneys. Her organs have shown significant recovery, a year and a half after undergoing the treatment.
Lupus causes the immune system to mistakenly attack the body's own tissues and organs, leading to symptoms such as joint pain, skin conditions, and severe organ damage. The experimental therapy works by genetically modifying a patient's own T-cells – a type of white blood cell – to target and destroy B-cells, which are responsible for producing the rogue antibodies in lupus.
After preparing the body with chemotherapy, the modified T-cells are reintroduced, effectively eradicating both healthy and diseased B-cells. Months later, new, healthy B-cells regenerate, resetting the immune system and allowing patients to experience sustained improvements in their symptoms.
The treatment is intensive, involving chemotherapy and inherent risks, but initial results show great promise. Of the first six patients treated, five remain in remission, with sustained improvements observed for over 18 months. One patient experienced a flare-up after 11 months but still saw overall symptom improvement. While the long-term duration of remission remains uncertain, experts are optimistic about this major breakthrough.
Dr Maria Leandro, a consultant rheumatologist at UCLH, believes that achieving consistent remission for three to five years would represent a significant gain for lupus patients. The potential for this treatment to extend to other debilitating autoimmune conditions, such as multiple sclerosis and rheumatoid arthritis, is also being explored – marking a hopeful new direction in the management of these complex diseases.